Wanbury informs about press release

20 Dec 2024 Evaluate
Wanbury has informed that pursuant to Regulation 30 (6) of $EBI (Listing Obligations and Disclosure Requirements) Regulations, Wanbury's Tanuku plant at Andhra Pradesh successfully completed ANVISA inspection (Brazil Health Regulatory Agency) started from 16.12.2024 to 19.12.2024 (4 days) for its API manufacturing facility. Inspection completed with zero observations which means no observation during the inspection process for 5 APis confirming strict adherence of cGMP practices at its state-of-the art API manufacturing facility. The Company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe since ANVISA (Agenica National De Vigilancia Sanitaria) is part of PIC (Pharmaceutical Inspection Convention). This is second international FDA inspection with zero observations this year after US FDA inspection completed in June 2024 at Patalganga plant also with zero observations. Wanbury is one of the largest manufacturer of Metformin HCI & Sertraline API in addition to other API's with few more are under final stage of development & set to be produced shortly in the said facility. This inspection validates management continued commitment to Quality of the APi's as per international regulations.

The above information is a part of company’s filings submitted to BSE.

Wanbury Share Price

283.50 -6.55 (-2.26%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.